Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CVE:HEM CVE:NSCI CVE:PAS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHEMHemostemixC$0.06C$0.06C$0.04▼C$0.16C$10.88M0.17824951,787 shs1,689 shsNSCINanalysis ScientificC$0.13C$0.14C$0.11▼C$0.26C$17.31M-0.51875260,513 shs80,711 shsPASPascal BiosciencesC$0.02-25.0%C$0.02C$0.02▼C$0.10C$984K1.5152,289 shs4,000 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHEMHemostemix0.00%0.00%-8.33%-26.67%-59.26%NSCINanalysis Scientific0.00%0.00%-16.67%-10.71%-51.92%PASPascal Biosciences0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHEMHemostemixC$0.06C$0.06C$0.04▼C$0.16C$10.88M0.17824951,787 shs1,689 shsNSCINanalysis ScientificC$0.13C$0.14C$0.11▼C$0.26C$17.31M-0.51875260,513 shs80,711 shsPASPascal BiosciencesC$0.02-25.0%C$0.02C$0.02▼C$0.10C$984K1.5152,289 shs4,000 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHEMHemostemix0.00%0.00%-8.33%-26.67%-59.26%NSCINanalysis Scientific0.00%0.00%-16.67%-10.71%-51.92%PASPascal Biosciences0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHEMHemostemix 0.00N/AN/AN/ANSCINanalysis Scientific 0.00N/AN/AN/APASPascal Biosciences 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHEMHemostemixN/AN/AC$0.01 per share10.77C($0.03) per shareN/ANSCINanalysis ScientificC$40.20M0.43C$0.01 per share8.93C$0.21 per share0.60PASPascal BiosciencesN/AN/AC$0.00 per share55.00C($0.02) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHEMHemostemix-C$5.00M-C$0.02N/AN/AN/AN/A80.07%-349.24%N/ANSCINanalysis Scientific-C$12.93M-C$0.05N/AN/AN/A-32.75%-38.02%-7.55%N/APASPascal BiosciencesN/A-C$0.01N/AN/AN/AN/AN/A-340.40%N/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthHEMHemostemixN/AN/AN/AN/AN/ANSCINanalysis ScientificN/AN/AN/AN/AN/APASPascal BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHEMHemostemix-66.090.240.48NSCINanalysis Scientific71.721.421.11PASPascal Biosciences882.790.030.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHEMHemostemixN/ANSCINanalysis Scientific0.03%PASPascal BiosciencesN/AInsider OwnershipCompanyInsider OwnershipHEMHemostemix10.43%NSCINanalysis Scientific3.95%PASPascal Biosciences15.43%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHEMHemostemixN/A197.80 millionN/ANot OptionableNSCINanalysis Scientific249138.46 millionN/ANot OptionablePASPascal Biosciences665.59 millionN/ANot OptionableHEM, NSCI, and PAS HeadlinesRecent News About These CompaniesChristie’s suspends auction of Pascal’s 1642 calculatorNovember 19, 2025 | thehindu.comChristie's Suspends Paris Sale Of Pascal 1642 CalculatorNovember 19, 2025 | barrons.comAvengers: Doomsday Report Reveals Pedro Pascal’s ‘Major’ RoleNovember 18, 2025 | yahoo.comPascal Engineering Inc. appoints Norio Kobayashi as vice presidentNovember 13, 2025 | ctemag.comCNerdist’s Nerdiest Man Alive: Pedro PascalNovember 7, 2025 | yahoo.comEva Victor Joins Pedro Pascal & David Harbour In Searchlight’s ‘Behemoth!’October 17, 2025 | msn.comPedro Pascal Crowned 2025's ‘Sexiest Man Alive’ FrontrunnerOctober 17, 2025 | msn.comPete Davidson Defends Pedro Pascal From Online Trolls Who Say He’s In Everything: “You’ve Got To Give Someone Time To Adjust To That New Level Of Fame”September 27, 2025 | deadline.comDPete Davidson defends Pedro Pascal against online criticsSeptember 27, 2025 | msn.comPete Davidson Says Social Media “Can’t Wait” to Turn On Celebs Like Pedro PascalSeptember 27, 2025 | vanityfair.comVPete Davidson defends 'The Last of Us' star Pedro PascalSeptember 26, 2025 | msn.comPete Davidson Predicts Fans Will “Turn” on Walton Goggins Similar to Pedro Pascal Oversaturation BacklashSeptember 26, 2025 | hollywoodreporter.comHPedro Pascal Gets Support From Unexpected Actor Amid Recent CriticismSeptember 26, 2025 | msn.comPete Davidson Calls Out Social Media for Turning on Pedro Pascal So Fast: He ‘Blows Up,’ Becomes ‘Daddy’ and Then Everyone’s Like ‘Go the F— Away’September 25, 2025 | variety.comVPete Davidson Defends Pedro Pascal From Online Trolls Who Say He’s In Everything: “You’ve Got To Give Someone Time To Adjust To That New Level Fame”September 25, 2025 | msn.comPete Davidson Defends Pedro Pascal from Online Critics, Says People 'Can't Wait' to Tear Down CelebritiesSeptember 25, 2025 | msn.comPedro Pascal and Baby Yoda Return to “Star Wars” in Action-Packed “The Mandalorian and Grogu” TrailerSeptember 24, 2025 | yahoo.comPedro Pascal, Baby Yoda return in 'Star Wars: The Mandalorian and Grogu' trailerSeptember 22, 2025 | abcnews.go.comPedro Pascal starrer 'The Mandalorian and Grogu' from 'Star Wars' universe trailer outSeptember 22, 2025 | news.webindia123.comNPedro Pascal Defends Jimmy Kimmel Amid ABC Suspension: "Standing With You"September 21, 2025 | msn.comMedia Sentiment Over Time Top HeadlinesView All HeadlinesAs Broadcom Eclipses $2 Trillion, Private Credit Giants Wants InBy Leo Miller | May 17, 2026The Smarter Way to Invest in AI Without Taking Extreme RiskBy Chris Markoch | May 31, 20263 Dividend Stocks Under $50 That Pay You to Wait Out InflationBy Chris Markoch | June 12, 20263 Most Upgraded Stocks Last Month According to MarketBeatBy Leo Miller | June 3, 2026A Market Rotation Toward Quality Will Benefit These 3 ETFsBy Nathan Reiff | June 8, 2026HEM, NSCI, and PAS Company DescriptionsHemostemix CVE:HEMC$0.06 0.00 (0.00%) As of 06/15/2026 12:45 PM EasternHemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.Nanalysis Scientific CVE:NSCIC$0.12 0.00 (0.00%) As of 06/15/2026 11:51 AM EasternNanalysis Scientific Corp. engages in the development, manufacture, and sale of magnetic resonance products in the United States, Canada, Europe, Asia, and internationally. The company operates through four segments: Nanalysis, RS2D, K'Prime, and Corporate. It offers nuclear magnetic resonance (NMR) spectrometers; software module packages; cutting-edge electronics components for precision analytical instruments; and services for its NMR technologies. It serves pharmaceutical, security, biotech, nutraceutical, chemical, food, materials, medical, and education industries. The company is headquartered in Calgary, Canada.Pascal Biosciences CVE:PASC$0.02 -0.01 (-25.00%) As of 12/5/2022Pascal Biosciences Inc., a biotechnology company, engages in the research and development of products for the treatment of cancer, and for the improvement of the immune system. The company's development portfolio includes PAS-403, a mitosis inhibitor that blocks cell division for the treatment of glioblastoma and brain metastases originating from other cancers; and PAS-393, an immune-stimulatory cannabinoid designed to restore the immunogenicity of tumor cells with checkpoint inhibitor therapy for use in cancer treatment. It is also developing a B-cell targeted antibody for acute lymphoblastic leukemia and B cell lymphomas; and cannabinoid therapeutic products for the treatment of COVID-19. The company has an exclusive license agreement with the University of Washington to develop a cannabinoid-based product for the treatment of glioblastoma multiforme and brain metastases; and a collaborative research agreement with SoRSE Technology Corporation to advance PAS-393 into clinical testing. Pascal Biosciences Inc. was incorporated in 2011 and is headquartered in Seattle, Washington. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas What's Behind the Social Media Controversy Surrounding IonQ? Mission Control: Floating In SpaceX's Record-Breaking Orbit 3 Dividend Increases Investors Can Actually Trust RH’s Strong Q1 Still Leaves Investors With One Big Question SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? Alphabet's Most Overlooked Division Just Had a Big Week Robinhood Wants a Bigger Role in IPOs—Here's Why It Matters Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
